Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

類似資料

• Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
  著者:: Ku, Bo Mi, 等
  出版事項: (2017)
• The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
  著者:: Ku, Bo Mi, 等
  出版事項: (2016)
• Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non‐small cell lung cancer
  著者:: Ku, Bo Mi, 等
  出版事項: (2021)
• EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
  著者:: Park, Sehhoon, 等
  出版事項: (2020)
• Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
  著者:: Ku, Bo Mi, 等
  出版事項: (2018)